Canopy Growth Corp vs Payoneer Global Inc — how do they compare? Canopy Growth Corp trades at $0.97 (market cap $398.46M), while Payoneer Global Inc trades at $7.11 (market cap $2.40B). The key difference: Payoneer Global Inc is far larger — about 6× Canopy Growth Corp's market cap, and Payoneer Global Inc is trading nearer its 52-week high, Canopy Growth Corp nearer its low. Which is the better fit depends on your goals.
| CGC | PAYO | |
|---|---|---|
Market Cap | $398.46M | $2.40B |
Sector | Health | Technology |
52-Week High | $1.92 | $7.42 |
52-Week Low | $0.86 | $4.27 |
Enterprise Value | $337.90M | $2.14B |
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $0.96, down 1.15% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses against expectations. Cash flow remains negative, but the balance sheet shows improving debt-to-asset ratios, down to 33.13% in 2025 from 53.61% in 2023.
The outlook is cautious; while cost-cutting and restructuring efforts are underway, profitability remains elusive, and the stock faces risks including potential delisting due to low share price. Analyst sentiment is divided, with 33% recommending buy, 41% hold, and 26% sell. Investors should weigh the potential for a turnaround against significant operational and regulatory challenges in the cannabis sector.
Payoneer (PAYO) trades at $7.10, flat on the day, with a bullish technical signal driven by moving averages. The company reported Q1 2026 EPS of $0.06, beating expectations, but missed in Q3 and Q4 2025. Revenue grew to $821.16M in 2025, though net income fell to $73.19M. Analysts maintain a 60% buy rating with an $8.20 consensus target. Recent news highlights a $2.75B acquisition by Nuvei and expansion into India, boosting sentiment but raising fairness concerns.
Outlook is mixed: the Nuvei deal offers a near-term exit at $7.40, but growth initiatives like India expansion provide long-term potential. Risks include integration challenges, margin pressure, and shareholder litigation over acquisition terms. The stock's current price near the low target suggests limited upside unless the deal is renegotiated or standalone execution improves.
Trailing returns across standard periods
Latest headlines on both assets
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →